IMS recognizes that each client’s environment and competitive situation is different.
EXAMPLES:
-
Licensing-in a first oncology product
-
Launching a first oncology product
-
Defending share for what had been an exclusive product
-
Introducing a new indication into unfamiliar terrain
-
Expanding a strong franchise
And that more accurate, more strategic decisions need to be made about:
-
Selecting the right molecules from the right partners for the best licensing and acquisition deals
-
Determining the most strategic approaches to developing products and portfolios
-
Optimizing revenue through a product’s entire life cycle
-
Designing and selecting first and subsequent indications, aligning clinical trial objectives, reaching out to KOLs, and planning for publications and presentations to support speed-to-market and rapid uptake
-
Integrating this planning into robust, flexible launch strategies (whether a new product, new delivery approach, new indication or even a re-positioning)
From our evidence-based analyses, we can help you design the optimal strategy for your product and/or portfolio development
Click to enlarge
Through numerous successful engagements working with pharma on oncology projects, we have developed considerable expertise in the following areas: